DS-1471 / Daiichi Sankyo - LARVOL DELTA

A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors (ESMO 2024) - P1 | "Safety measures for primary outcomes in this study include dose-limiting toxicities and treatment-emergent adverse events. Secondary outcome measures for both parts include best overall response, time to response, duration of response, progression-free survival, and overall survival."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • BSG

A Study of DS-1471a In Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

Preclinical pharmacokinetic-pharmacodynamic modeling guides setting of the human starting dose of DS-1471a, a novel anti-CD147 antibody. (AACR-NCI-EORTC 2023) - No abstract available

PK/PD data • Preclinical • Oncology

Novel Anti-CD147 Antibody DS-1471a Exerts Antitumor Effect in Hepatocellular Carcinoma Patient Derived Xenograft Models and its Efficacy Correlates with the Expression of CD147. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor